Study #2022-0813
Phase II trial of Sacituzumab Govitecan in recurrent and/or metastatic salivary gland cancers
MD Anderson Study Status
Enrolling
Treatment Agent
Sacituzumab Govitecan
Description
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gland, Salivary Gland Cancers
Study phase:
Phase II
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-421-1842
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.